Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
NAC (N-Acetylcysteine): Evidence Summary
Evidence summary for NAC (N-Acetylcysteine) across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to NAC (N-Acetylcysteine) overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Acetaminophen overdose antidote | Tier A | 20 | Definitive efficacy for hepatoprotection; standard of care worldwide |
| Mucolytic (CF, COPD, bronchitis) | Tier A | 30 | FDA-approved since 1963; modest reduction in COPD exacerbations |
| Psychiatric adjunct (OCD, addiction) | Tier B | 15 | Meta-analysis of 15 RCTs shows modest adjunct benefit |
| Contrast nephropathy prevention | Tier C | 20 | 2021 meta-analysis of 20 RCTs found no significant benefit |